Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report sent to investors on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $36.00 target price on the stock.

Several other brokerages have also commented on AVTX. Wedbush reiterated an “outperform” rating and issued a $18.00 price target on shares of Avalo Therapeutics in a research note on Thursday, March 20th. HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. BTIG Research assumed coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Piper Sandler assumed coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.00.

Avalo Therapeutics Stock Up 11.9 %

NASDAQ:AVTX opened at $8.54 on Tuesday. Avalo Therapeutics has a 1 year low of $4.60 and a 1 year high of $34.46. The stock has a 50-day simple moving average of $7.51 and a 200-day simple moving average of $9.14.

Institutional Trading of Avalo Therapeutics

Large investors have recently bought and sold shares of the business. Ikarian Capital LLC raised its holdings in shares of Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after buying an additional 915,629 shares during the last quarter. RA Capital Management L.P. acquired a new position in Avalo Therapeutics in the 3rd quarter valued at about $9,186,000. Geode Capital Management LLC raised its stake in Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock valued at $779,000 after acquiring an additional 94,742 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Avalo Therapeutics in the 4th quarter valued at approximately $446,000. Finally, Walleye Capital LLC acquired a new position in shares of Avalo Therapeutics in the fourth quarter valued at approximately $145,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.